论文部分内容阅读
目的分析耐多药肺结核患者的治疗转归,为耐多药肺结核防治工作的规范管理提供依据。方法对2009年7月—2010年6月纳入全球基金结核病项目治疗的68例耐多药肺结核患者2年后的转归进行分析。结果68例耐多药肺结核患者中,治愈44例,完成治疗1例,治疗成功率66.18%,死亡5例,因不良反应中止5例。复发、初治失败和复治失败患者的治愈率分别为30.00%、75.86%和65.38%,其中复发和初治失败患者间的治愈率差异有统计学意义(P<0.05)。结论耐多药肺结核治愈率有待提高,需进一步规范耐多药肺结核诊疗与管理,及时处置不良反应,提高患者治疗依从性。
Objective To analyze the treatment outcome of multidrug-resistant pulmonary tuberculosis patients and provide basis for the standard management of multidrug-resistant tuberculosis prevention and treatment. Methods The outcomes of 68 multidrug-resistant pulmonary tuberculosis patients treated in the Global Fund TB program from July 2009 to June 2010 were analyzed after 2 years. Results Of 68 patients with MDR-TB, 44 were cured, 1 was completed, the success rate was 66.18%, 5 died and 5 were discontinued due to adverse reactions. The cure rates of recurrence, initial treatment failure and retreatment failure were 30.00%, 75.86% and 65.38%, respectively. There was significant difference in the cure rate between recurrence and initial failure (P <0.05). Conclusions The cure rate of multidrug-resistant pulmonary tuberculosis needs to be improved. It is necessary to further regulate the diagnosis and management of multidrug-resistant pulmonary tuberculosis, promptly dispose of adverse reactions and improve patient compliance.